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Abstract
The definition of heart failure with preserved ejection fraction (HFpEF) has evolved from a clinically 
based “diagnosis of exclusion” to definitions focused on objective evidence of diastolic dysfunction and/ 
/or elevated left ventricular filling pressures. Despite advances in our understanding of HFpEF patho-
physiology and the development of more sophisticated imaging modalities, the diagnosis of HFpEF 
remains challenging, especially in the chronic setting, given that symptoms are provoked by exertion and 
diagnostic evaluation is largely conducted at rest. Invasive hemodynamic study, and in particular — 
invasive exercise testing, is considered the reference method for HFpEF diagnosis. However, its use is 
limited as opposed to the high number of patients with suspected HFpEF. Thus, diagnostic criteria for 
HFpEF should be principally based on non-invasive measurements. As no single non-invasive variable 
can adequately corroborate or refute the diagnosis, different combinations of clinical, echocardiographic, 
and/or biochemical parameters have been introduced. Recent years have brought an abundance of HF-
pEF definitions. Here, we present and compare four of them: 1) the 2016 European Society of Cardiol-
ogy criteria for HFpEF; 2) the 2016 echocardiographic algorithm for diagnosing diastolic dysfunction; 
3) the 2018 evidence-based H2FPEF score; and 4) the most recent, 2019 Heart Failure Association 
HFA-PEFF algorithm. These definitions vary in their approach to diagnosis, as well as sensitivity and 
specificity. Further studies to validate and compare the diagnostic accuracy of HFpEF definitions are 
warranted. Nevertheless, it seems that the best HFpEF definition would originate from a randomized 
clinical trial showing a favorable effect of an intervention on prognosis in HFpEF. (Cardiol J 2020; 27, 
5: 449–468)
Key words: diagnosis, diastolic function, E/e’ ratio, left atrial pressure, pulmonary  
capillary wedge pressure, natriuretic peptides, atrial fibrillation
Introduction
Heart failure with preserved ejection fraction 
(HFpEF) is one of the hot topics in modern cardi-
ology. Entering “HFpEF”, “diastolic dysfunction”, 
or related terms into the MEDLINE (Medical 
Literature Analysis and Retrieval System Online) 
database results in over 12,000 citations, with 
a sharp increase in recent years. Despite well-
-defined demographic and clinical characteristics of 
HFpEF patients, as well as ongoing research and 
discussion on the essence of HFpEF, no uniform 
diagnostic criteria have been widely accepted, nor 
has any treatment been shown to improve progno-
sis [1]. Different definitions have been proposed 
by scientific societies or adopted in randomized 
clinical trials [1–11]. These definitions vary greatly 
in their approach to the diagnosis (clinically based 
vs. focused on objective evidence of diastolic 
dysfunction and/or elevated left ventricular [LV] 
filling pressure, with different combinations of 
parameters used in each definition), which may 
reflect limitations of our understanding of HFpEF 
pathophysiology but also different stages of HFpEF 
continuum with some definitions aiming at pre-
clinical diastolic dysfunction, and some directed 
at clinically overt, advanced HFpEF (Fig. 1) [12, 
13]. In everyday clinical practice, confirming or 
excluding HFpEF poses a considerable challenge 
with a potential for both overdiagnosis (mostly in 
primary care and in patients hospitalized for acute 
dyspnea) and underdiagnosis (especially in stable, 
uncongested, elderly patients with exertional 
symptoms) [14–24]. The abundance of HFpEF defi-
nitions might cause even more confusion among 
non-HF specialists. This article is an attempt to 
present the most up-to-date diagnostic criteria for 
chronic HFpEF, compare different definitions, and 
summarize their strengths and limitations.
Why is it difficult to establish  
diagnostic criteria for HFpEF?
As shown in Figure 1, different diagnostic 
parameters reflect different pathomechanisms 
and different stages of HFpEF. Furthermore, most 
parameters are not specific for HFpEF (Table 1 
[4, 24–47]). Thus, no single variable, echocardio-
graphic or biochemical, can adequately corroborate 
or refute the diagnosis [4, 5]. Moreover, for dif-
ferent parameters, no clear cut-off points can be 
defined because most of them are continuously 
distributed within a population and may vary de-
pending on age, gender, body surface area, body 
mass index (BMI), heart rhythm, kidney function, 
and the presence of cardiac and extra-cardiac 
comorbidities [5]. Notably, choosing a “lower” 
value as a threshold for diagnosis would increase 
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Figure 1. Natural history of heart failure with preserved ejection fraction (HFpEF) with corresponding echocardio-
graphic and invasively measured parameters. For clarity and to enhance educational value, separate pathophysi-
ological stages have been distinguished with parameters allocated to each stage. In reality, these stages overlap and 
can change with time, volume status, and level of physical activity. The diagram does not include more sophisticated 
echocardiographic and invasive parameters, and it does not refer to all postulated pathomechanisms (such as micro-
vascular inflammation or cardiometabolic abnormalities). Dotted line indicates parameters (measured during right 
heart catheterization [RHC]) that do not constitute criteria for the diagnosis of HFpEF by any definition. Stages of HF 
according to the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have 
been shown [2]; DD — diastolic dysfunction; dPAP — diastolic pulmonary artery pressure; GLS — global longitudinal 
strain; HF — heart failure; LAP — left atrial pressure; LAVI — left atrial volume index; LHC — left heart catheteriza-
tion; LVEDP — left ventricular end-diastolic pressure; LVH — left ventricular hypertrophy; LVMI — left ventricular 
mass index; mPAP — mean pulmonary artery pressure; PCWP — pulmonary capillary wedge pressure; RV — right 
ventricle; RWT — relative wall thickness; sPAP — systolic pulmonary artery pressure; TAPSE — tricuspid annular 
plane systolic excursion; TRV — tricuspid regurgitation velocity.
Table 1. Factors affecting natriuretic peptides and chosen echocardiographic parameters assessed in 
the course of a diagnostic work-up for heart failure with preserved ejection fraction.
Parameter Pathophysiologic rationale  
and clinical significance
Limitations and confounding factors
NPs The main trigger for release is increased LV  
end-diastolic wall stress
1. In chronic HFpEF, NPs can be false negative:
 — NPs are more sensitive for HFrEF: LV wall 
stress is proportional to LV radius and in-
versely proportional to LV wall thickness 
therefore NP levels are lower in HFpEF  
(hypertrophic, non-dilated LV) than in HFrEF 
(dilated LV); LV hypertrophy in HFpEF  
develops to reduce wall stress
 — NPs are more sensitive for acute HF
 — Obesity and female gender are associated 
with lower NPs 
2. NPs can be false positive in the absence  
    of HFpEF:
 — Older age, AF, kidney disease, valvular heart 
disease, pulmonary disease, and arterial 
pulmonary hypertension can result in  
elevated NPs
3. NP levels can fluctuate in time
Æ
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Table 1 (cont.). Factors affecting natriuretic peptides and chosen echocardiographic parameters  
assessed in the course of a diagnostic work-up for heart failure with preserved ejection fraction.
Parameter Pathophysiologic rationale  
and clinical significance




e’ reflects LV relaxation  — Measurement is angle-dependent
 — e’ decreases with age
 — e’ is unreliable in patients with mitral annu-
lar calcifications or prosthetic valves or rings
 — e’ can be influenced by regional wall motion 
abnormalities due to myocardial ischemia
 — TDI-derived parameters are much less 
preload-dependent than mitral inflow; 
however, e’ may increase with increased 
preload, mainly in subjects with normal LV 
function
 — in healthy subjects, e’ also increases with 
exercise-induced tachycardia
E and E/A The E wave reflects LA-LV pressure gradient  
during early diastole, which depends on LA  
pressure and LV relaxation/LV stiffness
— E velocity is highly dependent on preload
 — tachycardia affects E velocity and can lead 
to fusion of E/A waves
 — E/A ratio not applicable in AF
 — E/A ratio is age-dependent
 — without additional variables normal and 
pseudonormal mitral inflow pattern are  
difficult to differentiate
 — increased E velocity and pseudonormal/re-
strictive mitral inflow pattern can be second-
ary to other causes, including in particular 
moderate-to-severe mitral regurgitation, 





The most appropriate echocardiographic  
parameter reflecting LV filling pressure:
 — E/e’ ≥ 15 has a high positive predictive  
value for elevated PCWP
 — E/e’ is less dependent on:
• preload than E and e’ velocities
• heart rate than E velocity
• age than e’ velocity
 — Correlation with invasive measurements is 
moderate with a “grey zone” for intermedi-
ate values of 9–14
LAVI Enlarged LA reflects longstanding elevation  
of LA pressure
 — LA enlargement can be secondary to other 
causes, including in particular AF, mitral 
valve diseases, volume overload (e.g. in  
kidney disease), etc. (reduced specificity)
 — LA enlargement develops with time and  
can be absent at an early stage of HFpEF 
(reduced sensitivity)
 — Correlation with invasive measurements  
is moderate
 — TRV measurement may be difficult or  
impossible (e.g. in the case of absent or 
trivial tricuspid regurgitation or suboptimal 
acoustic window)
 — TRV and echocardiographically estimated 
sPAP increase with age
 — TRV is preload dependent
 — increase in TRV and sPAP can be secondary 
to other causes, including left heart disease 
other than HFpEF, pulmonary disease,  
pulmonary embolism and chronic  
thromboembolic pulmonary hypertension, 
pulmonary arterial hypertension, fluid  
overload, etc. 
 — massive TR can result in low systolic RV-RA 










TRV is used for estimation of:
 — echocardiographic probability of pulmonary 
hypertension (as per 2015 ESC/ERS  
guidelines)
 — sPAP using simplified Bernoulli equation:
    sPAP = 4 × TRV2 + estimated right atrial  
    pressure
Based on references: [4, 24–47]. AF — atrial fibrillation; ERS — European Respiratory Society; ESC — European Society of Cardiology;  
HF — heart failure; HFpEF — heart failure with preserved ejection fraction; HFrEF — heart failure with reduced ejection fraction; LA — left 
atrium; LV — left ventricle; NP — natriuretic peptide; PCWP — pulmonary capillary wedge pressure; RA — right atrium; RV — right ventricle; 
sPAP — systolic pulmonary artery pressure; TDI — tissue Doppler imaging; TR — tricuspid regurgitation; TRV — tricuspid regurgitation velocity
452 www.cardiologyjournal.org
Cardiology Journal 2020, Vol. 27, No. 5
sensitivity at the expense of lower specificity, while 
setting a “higher” threshold would increase speci-
ficity at the expense of lower sensitivity. Thus, 
establishing cut-offs for echocardiographic vari-
ables and natriuretic peptides (NPs), though based 
on comparisons with invasive measurements, is 
inevitably arbitrary. The above considerations 
regarding adoption of cut-off points refer even to 
the “gold standard” of HFpEF diagnosis — heart 
catheterization [48, 49]. Invasive hemodynamic 
assessment is considered a reference investiga-
tion for diagnosing HFpEF [5, 12, 28]. However, 
it has limited availability compared to the large 
number of patients requiring diagnostic evaluation 
for this highly prevalent disease. Other limitations 
include unknown reproducibility and a question-
able risk/benefit ratio of an invasive study in view 
of the lack of specific HFpEF treatment [12, 49]. 
Hence, ideally, in most patients, diagnosis should 
be made based on non-invasive testing. However, 
validation of NPs and echocardiographic indices of 
HFpEF shows their relatively poor correlation with 
invasive hemodynamic measurements [4, 24–30, 
39, 44–46, 50]. Among different echocardiographic 
variables, the E/e’ ratio is considered the most ap-
propriate for approximation of LV filling pressures, 
but its agreement with invasive measurements 
is only moderate [24–30]. Similarly, echocardio-
graphic estimation of pulmonary artery pressure 
is not very accurate compared to right heart cath-
eterization (RHC) [44–46]. This, again, explains 
the need for an algorithm including a combination 
of different non-invasive variables rather than 
a single parameter to diagnose HFpEF. 
Another problem is that NP concentrations 
as well as echocardiographic indices of diastolic 
function and left atrial (LA) pressure can change in 
time, and therefore a single measurement of a given 
parameter does not provide definitive conclusions. 
Repeated measurements of NPs can show up to 
100% variability in concentration in an individual 
patient [5, 40]. Mitral inflow velocities, tricuspid 
regurgitation velocity (TRV), and to a lesser extent 
LA volume index (LAVI) and e’ velocities can also 
change over time depending on preload and/or 
heart rate [31–34, 41–47]. Another issue regard-
ing echocardiographic measurements would be 
intra- and interobserver variability [51–53]. Impor-
tantly, in chronic HFpEF, symptoms are observed 
during physical exertion, and thus measurements 
obtained at rest can lead to false negative results. 
Most non-invasive HFpEF definitions refer to as-
sessment at rest with the possibility to proceed 
to exercise echocardiography if the results are 
inconclusive or if the risk is deemed intermediate 
[1, 4, 5]. Notably, when invasive exercise testing 
was implemented as a reference method, among 
patients finally diagnosed with HFpEF, almost half 
displayed elevation in pulmonary capillary wedge 
pressure (PCWP) only during exercise [24, 54]. 
This indicates that even the “gold standard” of 
HFpEF diagnosis, invasive hemodynamic study, 
can yield a high proportion of false negative results 
if performed only at rest. 
The aforementioned problems are mirrored 
by a relatively poor agreement between different 
HFpEF diagnostic criteria: a patient diagnosed 
with HFpEF according to one definition, may be 
reclassified as not having HFpEF according to 
another [19, 21–24, 55]. Moreover, non-invasive 
HFpEF definitions vary significantly in their accu-
racy in identifying patients with invasively proven 
HFpEF, as well as in their predictive value for fu-
ture cardiovascular events [19, 20–24, 55]. It seems 
that the best “validation” of a HFpEF definition 
would be a positive result of a randomized clinical 
trial showing a favorable effect of an intervention 
on prognosis in HFpEF — inclusion criteria in 
such a trial could automatically become diagnostic 
criteria for HFpEF.
The first step towards a modern  
definition: The 2016 ESC guidelines
The 2016 European Society of Cardiology 
(ESC) HF guidelines were revolutionary by dis-
tinguishing three clinical syndromes: HF with 
reduced (HFrEF), preserved (HFpEF), and mid-
range ejection fraction (EF), with an unequivocal 
definition of each of these clinical entities [1]. The 
diagnosis of chronic HFpEF in a patient with an EF 
of ≥ 50% required the presence of HF symptoms 
and/or signs, elevation of NPs (B-type NP [BNP] 
≥ 35 pg/mL or N-terminal pro-BNP [NT-proBNP] 
≥ 125 pg/mL), and at least one of the follow-
ing echocardiographic criteria: LA enlargement 
(LAVI > 34 mL/m2), LV hypertrophy (by LV mass 
index [LVMI]), or diastolic dysfunction (by E/e’ 
ratio and e’) [1]. Given the low specificity of LA 
enlargement and NP exclusionary cut-off points 
adopted in the guidelines, those criteria could be 
perceived as relatively “mild” with some potential 
for overdiagnosis. However, it seems reasonable 
for a new definition to include a wider spectrum of 
patients facilitating their accurate characterization 
and a thorough analysis to identify more specific 
subgroups. On the other hand, the definition itself 
was based on assessment at rest, which, in patients 
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with exertional symptoms, may have led to false 
negative results. In fact, in well compensated pa-
tients with HFpEF confirmed by invasive exercise 
testing, its sensitivity was found to be only 60% 
and specificity 75% [24]. 
An echocardiographic algorithm for  
the diagnosis of diastolic dysfunction: 
The 2016 ASE/EACVI recommendations
In 2016, less than two months after the release 
of the ESC guidelines on HF, the American Soci-
ety of Echocardiography (ASE) and the European 
Association of Cardiovascular Imaging (EACVI) 
published recommendations on the echocardio-
graphic evaluation of diastolic function (an update 
of a previous document from 2009) [4, 56]. A sim-
ple algorithm was proposed for echocardiographic 
assessment of diastolic function in patients with 
an EF of ≥ 50% (Fig. 2A). The algorithm was 
based on four easily obtainable echocardiographic 
parameters: two tissue Doppler imaging (TDI)-
derived, direct indices of LV diastolic dysfunction 
(reduced e’ velocity and increased E/e’ ratio) and 
two “indirect” parameters secondary to elevation 
of LA pressure (increased LAVI and TRV) [4]. 
Compared to the ESC guidelines, the ASE/EACVI 
algorithm did not account for LV hypertrophy nor, 
understandably, NP concentrations. Nevertheless, 
it was more specific for diastolic dysfunction, due 
to the requirement of three or four positive crite-
ria to satisfy the definition, compared to only one 
positive echocardiographic criterion required to 
meet the ESC definition [1, 4, 24]. The ASE/EACVI 
algorithm also enabled echocardiographic esti-
mation of LA pressure and grading of diastolic 
dysfunction based largely on mitral inflow pattern 
(Fig. 2B) [4]. In patients with dyspnea and grade I 
diastolic dysfunction (normal estimated LA pres-
sure at rest), exercise echocardiography was 
recommended [4]. Importantly, the ASE/EACVI 
algorithm is the only one among the four discussed 
in this document which is designed for identifying 
and grading diastolic dysfunction rather than diag-
nosing HFpEF as a clinical syndrome. 
The ASE/EACVI algorithm was validated 
against invasive measurements in a few studies, 
with sensitivity for elevation of resting LV filling 
pressures ranging from 69% to 87% and specificity 
ranging from 74% to 88%, which was significantly 
superior to clinical assessment [21–23]. However, 
when validated against invasive exercise testing, 
its sensitivity dropped to 34% (maintaining a high 
specificity of 83%) [24].
Evidence-based assessment of HFpEF 
probability: The 2018 H2FPEF score
Contrary to other HFpEF definitions based on 
expert consensus opinion, the H2FPEF score was 
derived from a cohort of 414 patients with an EF 
of ≥ 50%, who were referred for exercise RHC for 
unexplained dyspnea in Mayo Clinic (Rochester, 
MN, USA) [54]. The H2FPEF score includes six 
dichotomized, widely available variables (four 
clinical and two echocardiographic), which, if posi-
tive, are attributed one point, with the exception 
of atrial fibrillation (AF) and obesity (BMI of > 30 
kg/m2), which are attributed three and two points, 
respectively (Table 2). Thus, the maximum score 
is nine points. For each score, the probability of 
invasively confirmed HFpEF was calculated, allow-
ing justifiable exclusion of HFpEF in patients with 
total scores of 0–1, and establishing its diagnosis 
with reasonably high confidence (likelihood of 
> 90%) at scores of 6–9 [54].
In the original study, the H2FPEF score proved 
superior to the 2016 ESC definition, allowing ac-
curate discrimination of HFpEF from noncardiac 
causes of dyspnea with area under the curve (AUC) 
in the receiver operating characteristic (ROC) 
analysis of 0.84 and 0.89 in the derivation and 
validation cohort, respectively [54]. Interestingly, 
inclusion of NT-proBNP cut-off points did not 
incrementally add diagnostic ability to the score 
[54]. This again confirms that, contrary to acute 
symptom exacerbation, in ambulatory patients with 
stable, exertional dyspnea, the discriminative value 
of NP measurements for HFpEF is relatively low 
because chronic HFpEF patients may have low 
NP concentrations, and patients with normal LV 
diastolic function can have elevated NPs due to AF 
or other comorbidities [35–40]. 
In subsequent studies, the H2FPEF score 
showed high sensitivity for clinically ascertained 
diagnosis of HFpEF, as well as predictive value for 
future HF-related events both in HFpEF and in 
non-HF patients with cardiovascular risk factors 
[57–60].
A comprehensive, stepwise  
approach to diagnosis:  
The 2019 HFA-PEFF algorithm 
In 2019, the Heart Failure Association (HFA) 
of the ESC released a consensus recommendation 
for the diagnosis of HFpEF [5]. The proposed 
HFA-PEFF algorithm, presented in Figure 3, is 
a stepwise approach, including:
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Figure 2. The 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging (ASE/ 
/EACVI) diagnostic algorithm for: A. The diagnosis of diastolic dysfunction in patients with preserved ejection fraction, 
B. Grading of diastolic dysfunction and estimation of left atrial pressure (LAP) in patients with preserved ejection 
fraction and myocardial disease. Adopted from Nagueh et al., 2016 [4], modified; CAD — coronary artery disease; 
LAVI — left atrial volume index; TRV — tricuspid regurgitation velocity.
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 — step 1 —   P for Pretest assessment;
 — step 2 — E for Echocardiographic and NP 
score;
 — step 3 —   F1 for Functional testing in case of 
uncertainty;
 — step 4 —   F2 for Final etiology.
Step 1 (P): Pretest assessment 
This step is consistent with an initial diagnos-
tic work-up of patients presenting with dyspnea 
or other symptoms suggestive of HF, as recom-
mended by the 2016 ESC guidelines on HF [1, 5]. 
Its goal is to identify individuals with potential 
diagnosis of HFpEF and exclude (or identify) 
alternative causes of symptoms (such as HFrEF, 
valvular disease, coronary artery disease, arrhyth-
mias, pulmonary disease, anemia, etc.). This step 
encompasses clinical assessment, laboratory tests 
(including NPs if available), electrocardiogram, 
chest X-ray, and standard echocardiography. Clini-
cal assessment includes evaluation of symptoms as 
well as risk factors for HFpEF (older age, obesity, 
arterial hypertension, metabolic syndrome with 
prediabetes/diabetes) and coexisting conditions. 
On the one hand, some comorbidities may imitate 
HF symptoms, and on the other hand, some are 
highly prevalent in HFpEF and thus strongly sug-
gestive of HFpEF, even if they could themselves 
explain exertional dyspnea (obesity, AF). If NP 
measurement is available, lower cut-off points 
(BNP of 35 pg/mL or NT-proBNP of 125 pg/mL, 
consistent with the 2016 ESC guidelines on HF) 
are adopted in step 1 due to their higher sensitivity 
and negative predictive value [1, 5]. Still, almost 
one fifth of patients with invasively proven HFpEF 
had NT-proBNP below this threshold, and thus 
normal NP concentrations do not exclude chronic 
HFpEF, especially in obese patients [24, 35–40]. 
Standard echocardiography aims to exclude alter-
native cardiac causes of dyspnea, assess EF (with 
“preserved EF” defined as ≥ 50%), and identify 
features suggestive of HFpEF, such as nondilated 
LV with concentric remodeling or hypertrophy, and 
LA enlargement. If step 1 (P) indicates possible 
HFpEF, then step 2 (E) is indicated [5].
Step 2 (E): Echocardiographic and NP score
Step 2 is based on the HFA-PEFF scoring 
system with 0–2 points assigned for each of the 
three domains: 1) functional (echocardiography), 
2) morphological (echocardiography or, less fre-
quently, cardiac magnetic resonance), and 3) bio-
marker (NPs). In each domain, cut-offs for certain 
parameters have been proposed and attributed one 
(minor criterion) or two points (major criterion), 
as shown in Table 3. Importantly, one domain can 
contribute maximally two points, even if more 
major or minor criteria are fulfilled. A total score 
of 5–6 points is considered to be diagnostic for 
HFpEF, while a score of 0–1 points makes the 
diagnosis of HFpEF unlikely and should prompt 
assessment of other possible causes of symptoms. 
A score of 2–4 points requires further evaluation 
(step 3) using exercise testing (echocardiographic 
or invasive) [5]. 
In the HFA-PEFF score, different cut-offs 
for NPs and LAVI have been adopted for AF (vs. 
sinus rhythm), for e’ for patients aged ≥ 75 years 
(vs. younger patients), and, similarly to the ESC 
definition, for LVMI for women vs. men. For NPs, 
eight cut-off points are given: four for BNP and four 
for NT-proBNP, depending on heart rhythm (with 
cut-offs in AF three times higher than in sinus 
rhythm) and criterion type (major vs. minor) [5]. 
From the clinical perspective, the complexity of 
the score with multiple variables in each domain 
and diverse cut-off points for one variable might 
be considered a drawback hindering its use in eve-
Table 2. The H2FPEF score. Adopted from Reddy et al., 2018 [54], modified.
Clinical variable Value Points
H2 Heavy BMI > 30 kg/m2 2
Hypertensive 2 or more antihypertensive medicines 1
F Atrial Fibrillation Paroxysmal or persistent 3
P Pulmonary Hypertension sPAP > 35 mmHg* 1
E Elder Age > 60 years 1
F Filling Pressure E/e’ > 9* 1
H2FPEF score Sum: 0–9
*From Doppler echocardiography; BMI — body mass index; sPAP — systolic pulmonary artery pressure
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Figure 3. The HFA-PEFF diagnostic algorithm. Adopted from Pieske et al., 2019 [5], modified; HFpEF — heart failure 
with preserved ejection fraction; ECG — electrocardiogram.
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ryday practice. However, as stressed by the HFA 
Experts, not all parameters from each domain need 
to be available to calculate the score, and therefore 
the seeming abundance of parameters actually 
increases its practical utility because typically not 
all parameters are given in an echocardiographic 
report. Thus, HFpEF diagnosis actually requires 
only one major criterion from each domain (e.g. 
TRV > 2.8 m/s, LAVI > 40 mL/m2, and NT-proBNP 
> 660 pg/mL for patients with AF) or two major 
criteria and one minor criterion (e.g. E/e’ of ≥ 15, 
LAVI > 34 mL/m2, and NT-proBNP 125–220 pg/mL 
for patients with sinus rhythm). On the other hand, 
a definite exclusion of HFpEF would ideally neces-
sitate evaluation of all parameters.
Notably, the HFA-PEFF score has, for the first 
time, included reduced absolute global longitudinal 
strain (GLS), an index of impaired systolic function, 
as a criterion for HFpEF diagnosis. Up to two thirds 
of HFpEF patients show abnormal GLS despite 
preserved EF [61, 62]. This reflects the complexity 
of HFpEF pathophysiology, with preclinical systolic 
dysfunction as yet another contributor to HFpEF 
syndrome [63–65].
The HFA-PEFF score was validated in two 
independent studies [55, 66]. The first study in-
cluded two prospective cohorts and showed excel-
lent sensitivity (99% for low-likelihood category, 
i.e. a total of 0–1 points) and specificity (93% for 
high-likelihood category, i.e. a total of 5–6 points) 
of the score with an AUC of 0.90 [66]. However, 
final HFpEF diagnosis in this study was not based 
on invasive measurements but mostly on echocardi-
ography, NPs, and clinical judgement. Furthermore, 
both cohorts included patients with high pre-test 
probability of HFpEF with only a small control 
group of non-HFpEF patients (potential selection 
bias). Notably, more than one third of patients in 
both cohorts were classified in the intermediate-
likelihood category (a total of 2–4 points) with 














Age < 75 years:
   Septal e’ < 7 cm/s or  
   Lateral e’ < 10 cm/s
Age ≥ 75 years:
   Septal e’ < 5 cm/s or  
   Lateral e’ < 7 cm/s
or 
Average E/e’ ≥ 15
or
TRV > 2.8 m/s  
(sPAP > 35 mmHg)
LAVI:
   SR > 34 mL/m2
   AF > 40 mL/m2
or
RWT > 0.42 and LVMI: 
   M ≥ 149 g/m2
   W ≥ 122 g/m2
NT-proBNP:
   SR > 220 pg/mL
   AF > 660 pg/mL
BNP:
   SR > 80 pg/mL














   SR 29–34 mL/m2





   M > 115 g/m2, < 149 g/m2
   W > 95 g/m2, < 122 g/m2
or
LV wall thickness ≥ 12 mm
NT-proBNP:
   SR 125–220 pg/mL
   AF 375–660 pg/mL
BNP:
   SR 35–80 pg/mL
   AF 105–240 pg/mL
Select only one score from each domain
Total score: 
0–1 points: HFpEF unlikely Æ search for alternative causes of symptoms
2–4 points: intermediate probability Æ diastolic stress test (non-invasive or invasive)
5–6 points: HFpEF confirmed
AF — atrial fibrillation; BNP — B-type natriuretic peptide; GLS — global longitudinal strain; HFpEF — heart failure with preserved ejection  
fraction; LAVI — left atrial volume index;  LVMI — left ventricular mass index; M — men; NT-proBNP — N-terminal proBNP; RWT — relative 
wall thickness; sPAP — systolic pulmonary artery pressure; SR — sinus rhythm; TRV — tricuspid regurgitation velocity; W — women
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a need for step 3 of the HFA-PEFF algorithm to 
secure the diagnosis [66]. In the second study, the 
HFA-PEFF score was validated against exercise 
testing with invasive hemodynamic monitoring, 
showing only moderate accuracy, with an AUC 
of 0.73 [55]. One quarter of patients in whom 
HFpEF could have been ruled out based on the 
HFA-PEFF score (0–1 points) had elevated PCWP 
consistent with HFpEF diagnosis, and almost one 
fifth of patients deemed to have HFpEF by the 
score (5–6 points) had normal PCWP both at rest 
and during exercise [55].
Step 3 (F1): Functional testing  
in the case of uncertainty
Step 3 is performed in patients who were at-
tributed 2–4 points in the HFA-PEFF score (step 2), 
and encompasses exercise echocardiography and/ 
/or heart catheterization at rest and during exercise. 
Exercise echocardiography (preferably using 
a semi-supine bicycle) can show an elevation in 
LV filling pressures (by E/e’ ratio) during exer-
tion, which can be accompanied by an increase 
in pulmonary artery pressure (estimated using 
TRV). An increase in the E/e’ ratio to ≥ 15 adds 
two points to the HFA-PEFF score calculated in 
step 2. An increase in the E/e’ ratio to ≥ 15 with 
a peak TRV of > 3.4 m/s adds three points to the 
HFA-PEFF score. A combined score from step 2 
(E) and step 3 (F1) of five points or more confirms 
HFpEF diagnosis. If the combined score does not 
exceed five points, invasive hemodynamic as-
sessment is recommended. This includes right 
and/or left heart catheterization at rest, and — in 
the case of inconclusive results — exercise RHC. 
Diagnostic criteria for HFpEF include resting LV 
end-diastolic pressure (LVEDP) of ≥ 16 mmHg on 
left heart catheterization and/or mean PCWP of 
≥ 15 mmHg on RHC (of note, the cut-off point for 
PCWP is consistent with the 2016 ESC guidelines 
on HF but somewhat different from the threshold 
for postcapillary pulmonary hypertension adopted 
in the 2015 ESC guidelines on pulmonary hyper-
tension [PCWP of > 15 mmHg]) [1, 5, 46]. Given 
that elevation of LV filling pressure may be present 
only during exertion, normal resting LVEDP or 
PCWP do not exclude HFpEF [24, 54]. In such 
patients, exercise RHC using cycle ergometry 
is recommended, and an increase of PCWP to 
≥ 25 mmHg is considered diagnostic for HFpEF 
[5]. The 2019 HFA consensus document does 
not refer to the possible role of acute volume 
challenge during RHC in establishing HFpEF 
diagnosis [46].
Step 4 (F2): Final etiology
In most patients, HFpEF is associated with 
typical demographic and clinical presentation, and 
is related to common risk factors (older age, arterial 
hypertension, obesity, and metabolic syndrome), 
but in some patients HFpEF may be a manifesta-
tion of specific heart muscle diseases, for example 
hypertrophic cardiomyopathy, infiltrative cardio-
myopathies (such as amyloidosis, sarcoidosis, or 
hemochromatosis), storage diseases (such as Fabry 
disease, glycogen storage diseases, or Gaucher 
disease), radiation-induced cardiomyopathy, en-
domyocardial fibrosis, autoimmune diseases, and 
other genetic disorders. Such specific etiologies 
need always to be considered, especially in cases 
with atypical presentation or positive family his-
tory, and if suspected, should prompt implementa-
tion of advanced diagnostic measures. Depending 
on the suspected underlying cause of HFpEF, these 
might include cardiac magnetic resonance, 99mTc-
-DPD scintigraphy, positron emission tomography, 
cardiac or non-cardiac biopsies, and/or specific 
laboratory tests, including genetic testing [5].
Is the 2016 ESC definition still valid?
The 2016 ESC HFpEF definition was much 
more liberal and less specific than the 2019 criteria 
adopted by the HFA. The ESC definition required 
only one echocardiographic criterion to be ful-
filled, and cut-off points for LVMI and NPs were 
consistent with the 2019 HFA minor criteria [1, 5]. 
Thus, the 2016 ESC definition should have the 
advantage of higher sensitivity, and might be used 
for screening patients with symptoms suggestive 
of HF. The initial diagnostic work-up of a patient 
with suspected HF (including the cut-off points 
for NPs) proposed in the 2016 ESC HF guidelines 
was largely incorporated into step 1 (P) of the 2019 
HFA-PEFF algorithm [1, 5].
A comparison of HFpEF diagnostic criteria 
from different documents is shown in Table 4.
Are the 2019 HFA-PEFF score and the 
2016 ASE/EACVI algorithm compatible?
The 2016 ASE/EACVI algorithm refers to 
evaluation of LV diastolic function and relies purely 
on echocardiographic criteria [4]. On the contrary, 
the 2019 HFA-PEFF score was designed to diag-
nose HFpEF in symptomatic patients and requires 
both echocardiographic assessment and measure-
ment of NPs [5]. As presented in Table 5, cut-off 
points for e’ and the E/e’ ratio in the two algorithms 
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are comparable [4, 5]. However, given the differ-
ent rules of point attribution, as well as obligatory 
NP measurement in the HFA-PEFF score, the 
two algorithms are not interchangeable, and some 
patients diagnosed with HFpEF/diastolic dysfunc-
tion according to one of them might not necessarily 
fulfil criteria allowing its unequivocal diagnosis 
according to the other (see examples, Fig. 4). 
Nonetheless, patients diagnosed with diastolic 
dysfunction using the ASE/EACVI algorithm will 
have at least intermediate probability of HFpEF in 
the HFA-PEFF score (because they will score at 
least two points). Conversely, patients with HFpEF 
diagnosis based on the HFA-PEFF score (5–6 points) 
might theoretically have normal diastolic function 
according to the ASE/EACVI algorithm, e.g. if 
they had significant LV hypertrophy with high NP 
concentrations (major criteria) with preserved e’ 
velocities, low TRV, and LA that has not enlarged 
yet (E/e’ ratio is expected to be elevated with 
high NPs, although this is not always the case, see 
Fig. 4A). However, such a scenario seems less 
probable in clinical practice. Comparison of the 
diagnostic accuracy of the two algorithms, their 
mutual validation, and assessment of the propor-
tion of reclassified cases should be the aims of 
future studies.
With a wider spectrum of echocardiographic 
parameters and NP measurement, the 2019 HFA- 
-PEFF algorithm offers a more integrated approach 
to the diagnosis of HFpEF, which may prove more 
reliable, although this still needs to be confirmed. 
On the other hand, apart from diagnosing diastolic 
dysfunction (including preclinical diastolic dys-
function), the 2016 ASE/EACVI criteria enable its 
grading with an estimation of LA pressure, which, 
although not very accurate, is very useful in clini-
cal practice, especially for follow-up of HF patients 
and assessment of efficacy of diuretic treatment. 
Notably, this year, a modification of the 2016 ASE/ 
/EACVI algorithm was proposed by two of its authors, 
however, not as official recommendations [67].
Table 5. Cut-off points for tissue Doppler imaging-derived parameters and tricuspid regurgitation  
velocity (TRV) in different recommendations on the diagnosis of diastolic dysfunction.
Parameter HFpEF/diastolic dysfunction definition
2016 ESC  
guidelines
2016 ASE/EACVI  
recommendations
2019 HFA-PEFF  
score
Resting echocardiography major criterion:
e’ lateral [cm/s] < 10 < 10 < 10 *
e’ septal [cm/s] < 8 < 7 < 7 *
Average E/e’ ≥ 13 > 14 ≥ 15 **
TRV [m/s] – > 2.8 > 2.8
Exercise echocardiography
Average E/e’ > 13 > 14 *** ≥ 15
TRV [m/s] – > 2.8 > 3.4
*For patients < 75 years; **E/e’ between 9 and 14 is a minor criterion; ***or septal E/e’ > 15; ASE — American Society of Echocardiography;  
EACVI - European Association of Cardiovascular Imaging;  ESC — European Society of Cardiology;  HFA — Heart Failure Association;  
HFpEF — heart failure with preserved ejection fraction
Table 4. Comparison of types of criteria used to diagnose heart failure with preserved ejection fraction 
(HFpEF) according to different recommendations.
Criteria HFpEF/diastolic dysfunction definition








Clinical X X *
Echocardiographic X X X X
Natriuretic peptides X X
*The score is designed to diagnose HFpEF in stable, symptomatic patients. ASE — American Society of Echocardiography; EACVI — European 
Association of Cardiovascular Imaging; ESC — European Society of Cardiology; HFA — Heart Failure Association
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Figure 4. Comparison of the American Society of Echocardiography/European Association of Cardiovascular Imag-
ing (ASE/EACVI) algorithm and the HFA-PEFF score based on clinical cases. A. An 88-year-old man with exertional 
dyspnea, sinus rhythm, and CCS with a history of percutaneous coronary intervention. Resting echocardiography 
revealed EF of 51%, LVH (LVMI 125 g/m2, RWT 0.48), reduced e’ velocities with E/e’ of 11, LAVI of 40 mL/m2, and TRV 
of 2.71 m/s. NT-proBNP was 371 pg/mL. Based on the ASE/EACVI algorithm, echocardiography was inconclusive for 
the diagnosis of diastolic dysfunction (two of four criteria positive). Given E velocity of 0.5 m/s, estimated resting LA 
pressure can be classified as normal; therefore, symptoms could either be attributable to CCS or would require as-
sessment with diastolic stress test (see Fig. 2B). However, according to the HFA-PEFF score (a total of six points), the 
patient can be diagnosed with HFpEF without proceeding to stress test. B. A 51-year-old woman with sinus rhythm 
and exercise intolerance. Resting echocardiography revealed EF of 65%, concentric LV remodeling (LVMI 69 g/m2, 
RWT 0.49), normal e’ velocities with E/e’ of 6, and LAVI of 33 mL/m2 (LA volume of 54 mL, BSA of 1.64 m2). There 
was no detectable TR Doppler signal profile. NT-proBNP was 338 pg/mL. Based on the ASE/EACVI algorithm, the 
patient was classified as having normal diastolic function. However, according to the HFA-PEFF score, with a total of 
three points (two points for the biomarker domain and one point for the morphological domain), HFpEF probability 
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Do the European HFA-PEFF score  
and the American H2FPEF score  
refer to the same patients?
The two definitions share similarities: both 
use a combination of various parameters in the 
form of a scoring system, and both are based on 
a Bayesian approach, describing HFpEF likelihood 
rather than providing a straightforward diagnosis. 
Both are meant for evaluation of chronic, sympto-
matic patients (the H2FPEF score — those with 
unexplained dyspnea). However, there are some 
major differences between the two scores. First, 
the H2FPEF score is an evidence-based tool de-
rived and validated in patients referred for RHC, 
while the HFA-PEFF score is an expert consen-
sus-based concept. Second, the H2FPEF score is 
predominantly based on clinical profiles, while the 
idea behind the HFA-PEFF score is that hemody-
namic abnormalities in HFpEF can and should be 
objectivized by echocardiography and NPs [5, 54]. 
Thus, the H2FPEF score could make a convenient 
bedside screening tool incorporated as step 1 (P) 
into the HFA-PEFF algorithm. Another premise for 
the use of the H2FPEF score as a screening method 
is its high sensitivity, resulting from the fact that 
almost half of the HFpEF patients in the derivation 
cohort had early-stage HFpEF with elevation of 
LV filling pressures only during exertion [54, 57]. 
Third, the effect of AF on the probability of HFpEF 
seems discordant in the two scores: in the H2FPEF 
score the presence of AF significantly increases 
the likelihood of HFpEF, while in the HFA-PEFF 
score it necessitates higher cut-off points of NPs 
and LAVI, decreasing the probability of HFpEF 
diagnosis at lower values. Thus, the same patient 
might even be classified at the opposing ends of 
the spectrum of HFpEF probability by each of the 
two scores. An elderly patient with unexplained 
dyspnea, AF, and a BMI of > 30 kg/m2 would be 
attributed a total of six points in the H2FPEF score, 
satisfying the criteria for HFpEF, regardless of the 
echocardiographic result (and regardless of NP 
measurement, which is not required in this score) 
[54]. In the HFA-PEFF algorithm, such a patient 
would only complete step 1 (P) and would require 
Figure 4 (cont.). C. A 75-year-old woman with atrial fibrillation. Resting echocardiography revealed EF of 57%, con-
centric LVH (LVMI 111 g/m2, RWT 0.58), and e’ septal and lateral of 5 and 9 cm/s, respectively (reduced as per ASE/ 
/EACVI algorithm, but within the norm range for age as per HFA-PEFF score), with E/e’ of 16.4, LAVI of 42 mL/m2, and 
moderate TR with TRV of 2.73 m/s. NT-proBNP was 849 pg/mL. According to the ASE/EACVI algorithm, the patient 
has diastolic dysfunction. This is consistent with the result of the HFA-PEFF score (six points, diagnosis of HFpEF); 
BSA — body surface area; CCS — chronic coronary syndrome; EF — ejection fraction; HFpEF — heart failure with 
preserved ejection fraction; LA — left atrium; LAVI — left atrial volume index; LV — left ventricle; LVH — left ven-
tricular hypertrophy; LVMI — left ventricular mass index; NT-proBNP — N-terminal pro-B-type natriuretic peptide; 
RWT — relative wall thickness; TRV — tricuspid regurgitation velocity.
C
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a thorough echocardiographic and NP assessment 
using the HFA-PEFF score (step 2 [E]), with 
higher cut-offs for NPs and LAVI due to AF [5].
A comparison of the two scores in an Asian 
population demonstrated high specificities of both 
scores (81% for the HFA-PEFF score and 88% for 
the H2FPEF score) with significantly higher sen-
sitivity of the HFA-PEFF score (74%) than of the 
H2FPEF score (25%) [68]. This surprisingly low 
sensitivity of the H2FPEF score might be explained 
by the fact that Asian HFpEF patients are almost 
a decade younger and have a lower prevalence 
of obesity and AF (two and three points in the 
H2FPEF score, respectively) than their western 
counterparts [69]. Thus, predictive values of dif-
ferent scores may substantially vary depending on 
the population studied.
Practical considerations on clinical profiles
Analysis of the presented HFpEF definitions 
may lead to a few realizations regarding clinical char-
acteristics, including female sex, obesity, and AF. 
Heart failure with preserved EF is widely re-
garded as a disease of older women [70]. However, 
even though the proportion of women is higher 
than men in the HFpEF population (contrary to 
HFrEF), the incidence of HFpEF adjusted for age 
and other risk factors tends to be similar in women 
and men [16, 71–73]. Notably, female sex was not 
included as a criterion in any of the above presented 
scores or definitions [1–11, 54]. A higher propor-
tion of women among HFpEF patients might result 
from their higher life expectancy [72]. However, es-
trogen deficiency has been postulated as one of the 
contributors underlying HFpEF development in 
post-menopausal women [74–76]. Among HFpEF 
patients, women have smaller LV dimensions with 
poorer diastolic reserve and higher LV filling pres-
sures at rest and exercise [77].
Obesity should not be perceived as a sufficient 
explanation for breathlessness or low exercise 
capacity but as a strong risk factor of HFpEF 
[70, 71]. This is reflected by two points attrib-
uted for a BMI of > 30 kg/m2 in the H2FPEF 
score [54]. Importantly, obesity can lead to NP 
concentrations that are normal or close to nor-
mal, even in the presence of HFpEF [1, 36, 38]. 
Unfortunately, this was not accounted for in the 
HFA-PEFF score [5]. Based on observations 
from hemodynamic studies, the existence of 
a distinct, obese phenotype of HFpEF has been 
postulated recently [78, 79].
Atrial fibrillation is highly prevalent in HFpEF 
— even more prevalent than in HFrEF [16, 80, 
81]. This is because AF is not only a consequence 
of elevation of LA pressure and LA enlargement 
in the course of HF (regardless of EF), but also 
because AF and HFpEF share a common patho-
physiological background and risk factors (older 
age, obesity, hypertension, diabetes) [82, 83]. 
However, AF can also be regarded as an important 
confounder in diagnosing HFpEF; first, because 
it can lead to an increase in NPs and LAVI even 
in the absence of HFpEF, and second, because it 
hinders echocardiographic evaluation of diastolic 
function [5]. Thus, as mentioned above, different 
scores represent different approaches to AF: the 
more “clinical” H2FPEF score recognizes it as 
a risk factor, while the HFA-PEFF score sees it as 
a confounding factor [5, 54].
Last but not least, even modern HFpEF defi-
nitions are, to some extent, “diagnoses of exclu-
sion”. For example, the derivation cohort for the 
H2FPEF score included patients referred for RHC 
for “unexplained” dyspnea, i.e. after exclusion of 
HFrEF, valvular heart disease, pulmonary arterial 
hypertension, constrictive pericarditis, clinically 
relevant pulmonary disease, and other conditions 
that might have accounted for their symptoms [54]. 
Similarly, step 1 (P) of the HFA-PEFF algorithm 
assumes exclusion of other cardiac and non-cardiac 
causes of dyspnea [5]. This is understandable given 
the aforementioned low specificity of most cur-
rently available echocardiographic and biochemical 
parameters. Still, in the elderly, multimorbidity 
is highly prevalent, and even more so in patients 
with HFpEF [70–72]. A single patient may, and 
often does, have several comorbidities, apart from 
HFpEF, that might add to his/her symptoms, and all 
of them deserve recognition and treatment. Thus, 
validation of the presented HFpEF definitions 
should ideally be conducted in unselected cohorts 
of symptomatic patients.
HFpEF definitions in clinical trials
Table 6 presents inclusion criteria applied in 
major HFpEF randomized clinical trials, which 
are largely inconsistent with the definitions re-
viewed above. Those trials included also a subset 
of patients that we nowadays refer to as HF with 
mid-range EF [6–11]. Analyzing inclusion criteria 
in those studies, over the years, an evolution of 
HFpEF definition can be seen, from more clinically 
based to objectivized by echocardiography and NPs. 
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Interestingly, prior HF hospitalization was (and still 
is) a common (although not always obligatory) cri-
terion for inclusion, driven by the intent to recruit 
higher risk patients with more potential to prove 
benefits from treatment by event reduction. This 
approach also reflects the fact that HFpEF mani-
festation is more evident in the acute setting of 
symptom exacerbation, but on the other hand might 
have led to its overdiagnosis and loss of the effect 
of spironolactone on the primary endpoint in the 
TOPCAT (Treatment of Preserved Cardiac Func-
tion Heart Failure with an Aldosterone Antagonist) 
trial [8, 84]. For now, no treatment tested in clinical 
trials has demonstrated an improvement in survival 
in HFpEF, although some benefit was observed 
when analyzing other clinical endpoints (e.g. HF 
hospitalizations for candesartan, perindopril, and 
spironolactone) or specific HFpEF subpopulations 
(e.g. women for sacubitril-valsartan) [6, 8, 10, 85]. 
Similar to HFrEF, HFpEF is not a homogenous 
clinical entity, but encompasses a wide spectrum 
of underlying diseases ultimately leading to el-
evated LA pressure despite preserved EF. This 
heterogeneity of the HFpEF syndrome may, at 
least in part, account for disappointing results of 
clinical HFpEF trials [86]. It is postulated that the 
“one fits all” strategy may need to be changed to 
a more individualized approach based on pheno-
typic patient characterization including cardiac and 
non-cardiac comorbidities [87–91]. 















Clinical criteria  
(HF symptoms  
and signs)
NYHA II–IV for at 
least 4 weeks
NYHA II–IV for at 
least 4 weeks
≥ 1 HF symptom  




at least 30 days 
prior to screening 
visit, NYHA II–IV at 
screening visit




For a cardiac  
reason
For HF within  
6 months  
(not obligatory)
For HF within  
12 months  
(alternative to  
elevated NPs)
For HF within  
9 months  
(not obligatory)
For HF within  
12 months  
(alternative  
to LAE/LVH)







– LAE or LVH – LAE or LVH LAE or LVH
NT-proBNP –
 
– ≥ 360 pg/mL*  
(alternative to prior 
HF hospitalization 
within 12 months)
For pts with HF 
hospitalization 
within 9 months:
— pts without AF: 
> 200 pg/mL,
— pts with AF:  
> 600 pg/mL. 
For pts with no 
HF hospitalization 
within 9 months:
— pts without AF: 
> 300 pg/mL,






*or BNP ≥ 100 pg/mL. AF — atrial fibrillation; BNP — B-type natriuretic peptide; CHARM Preserved — Candesartan Cilexetil in Heart Failure As-
sessment of Reduction in Mortality and Morbidity; EMPEROR-Preserved — Empagliflozin Outcome Trial in Patients With Chronic Heart Failure 
With Preserved Ejection Fraction; HF — heart failure; I-PRESERVE — Irbesartan in Heart Failure and Preserved Ejection Fraction; LAE — left 
atrial enlargement; LVEF — left ventricular ejection fraction; LVH — left ventricular hypertrophy; NPs — natriuretic peptides; NT-proBNP — 
N-terminal pro-BNP; NYHA — New York Heart Association; PARAGON-HF — Prospective Comparison of ARNI with ARB Global Outcomes in 
HF With Preserved Ejection Fraction; pts — patients; TOPCAT — Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist
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Conclusions:  
Which definition shoud we use?
The abundance of diagnostic criteria for HFpEF 
results from uncertainty regarding its underly-
ing pathophysiology and lack of definition-guided 
treatment [1–11, 13, 54, 92]. At present, the 2019 
HFA-PEFF algorithm constitutes the most compre-
hensive HFpEF definition, and its widespread use 
should be supported [5]. However, the 2016 ESC 
guidelines on HF can still be used in step 1 (pre-
test assessment) of the HFA-PEFF algorithm [1]. 
Alternatively, implementation of the H2FPEF score 
in step 1 (P) might be advocated in patients with 
unexplained dyspnea, especially if NP measure-
ments are not readily available [54]. Thus, in 
patients with suspected HFpEF, we suggest us-
ing the 2016 ESC HFpEF definition or estimation 
of HFpEF probability with the H2FPEF score for 
screening purposes by general practitioners, in-
ternists, geriatricians, or general cardiologists (as 
step 1 [P]), and if positive, verification of diagnosis 
using step 2 ([E]; the HFA-PEFF score) and, when 
indicated, step 3 (F1) of the HFA-PEFF algorithm 
by an HF specialist.
The 2016 ASE/EACVI definition was less 
comprehensive than the new HFA-PEFF algorithm 
but had an important practical advantage: it enabled 
echocardiographers to establish or exclude the 
presence of diastolic dysfunction, grade it, and sum-
marize their conclusions in an echocardiographic 
report (simply the presence or absence of diastolic 
dysfunction at rest) [4]. This facilitated confirmation 
or exclusion of HFpEF diagnosis for clinicians who 
might not be familiarized with detailed echocar-
diographic indices of diastolic function. In the 2019 
HFA-PEFF score, echocardiographic parameters 
and NP concentrations are analyzed in conjunction, 
which potentially leads to some confusion among 
non-HF specialists, hindering everyday use of the 
score due to its complexity [5]. Thus, in patients 
evaluated for dyspnea, it might be reasonable for 
echocardiographers to summarize the results from 
the two echocardiographic domains (functional and 
morphological) of the HFA-PEFF score by providing 
the total number of points (0–4 out of 4 possible) 
in conclusions of an echocardiographic report. The 
attending physician could then simply add 0–2 points 
depending on NP concentration to obtain the final 
result of the HFA-PEFF score.
Studies validating the HFA-PEFF score 
against invasive measurements, with comparison 
to the ASE/EACVI algorithm and the H2FPEF 
score, are warranted. The future will show whether 
this HFpEF definition will hold or whether it will be 
replaced by new diagnostic criteria — maybe origi-
nating from a positive randomized clinical trial?
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